A groundbreaking clinical trial has demonstrated that a new drug, donanemab, can significantly slow cognitive decline in patients with early-stage Alzheimer’s disease. The drug, developed by Eli Lilly, targets amyloid plaques in the brain, a hallmark of Alzheimer’s, and has shown a 35% reduction in cognitive decline over 18 months compared to a placebo. This development marks a significant step forward in the fight against a disease that affects millions worldwide.
The trial involved 1,736 participants with early symptomatic Alzheimer’s, all of whom had confirmed amyloid buildup in their brains. Donanemab works by binding to and clearing these toxic plaques, which are believed to disrupt neural communication and contribute to memory loss. While the drug does not cure Alzheimer’s, it offers hope for delaying progression, allowing patients more time with preserved cognitive function.
However, the treatment is not without risks. Some participants experienced brain swelling or bleeding, known as amyloid-related imaging abnormalities (ARIA), a known side effect of amyloid-targeting therapies. Despite these risks, many experts believe the benefits outweigh the potential harms, especially for patients in the earliest stages of the disease.
Regulatory approval is pending, but if authorized, donanemab could join lecanemab (Leqembi) as one of the few disease-modifying treatments available. The medical community remains cautiously optimistic, emphasizing the need for further research to understand long-term effects and optimize patient selection.
You Might Be Interested In:
- Women Who Smoke Face Greater Surgery Risks – Doctors Urge Quitting Before Operations
- Women More Likely to Know About Weight-Loss Medications Than Men, Study Finds
- Rural Healthcare Crisis Deepens as Doctor Shortages Leave Women Without Vital Medical Care
